TY  - GEN
AU  - Holmes,F A
AU  - Valero,V
AU  - Walters,R S
AU  - Theriault,R L
AU  - Booser,D J
AU  - Gibbs,H
AU  - Fraschini,G
AU  - Buzdar,A U
AU  - Willey,J
AU  - Frye,D
AU  - Asmar,L
AU  - Hortobagyi,G N
TI  - Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results
SN  - 0923-7534
PY  - 1999///0811
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Bone Neoplasms
KW  - secondary
KW  - Breast Neoplasms
KW  - diagnosis
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Doxorubicin
KW  - administration & dosage
KW  - Drug Administration Schedule
KW  - Female
KW  - Follow-Up Studies
KW  - Heart Diseases
KW  - chemically induced
KW  - Humans
KW  - Infusions, Intravenous
KW  - Lung Neoplasms
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Paclitaxel
KW  - Severity of Illness Index
KW  - Soft Tissue Neoplasms
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1023/a:1008360406322
ER  -